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Kenrick Semple,1,3 Yu Yu,3 Dapeng Wang,3 Claudio Anasetti,2,4 Xue-Zhong Yu1,2,3,4Naturally occurring regulatory T cells (nTregs) suppress the development of graft-versus-host disease
(GVHD) and may spare graft-versus-leukemia (GVL) effect. Because nTreg is a rare population in a healthy
individual, the limited source and the non-selective suppression are major hurdles towards the application
of nTregs in the control of clinical GVHD after allogeneic hematopoietic cell transplantation (HCT). An alter-
native approach is to generate induced Tregs (iTregs) from na€ıve CD4 precursors, but the effectiveness of
iTregs in the control of GVHD is highly controversial and requires further investigation. The other critical
but unsolved issue in Treg therapy is how to achieve antigen (Ag)-specific tolerance that distinguishes
GVHD and GVL effects. To address the important issues on the effectiveness of iTregs and Ag-specificity
of Tregs, we generated Ag-specific iTregs and tested their potential in the prevention of GVHD in a pre-
clinical bone marrow transplantation (BMT) model. CD41CD251Foxp31 iTregs generated from OT-II
TCR transgenic T cells specific forOVA targetAg efficiently preventedGVHD induced by polyclonal Teffector
cells (Teffs) only in the allogeneic recipients that expressOVA protein but not inOVA- recipients. The efficacy
of these Ag-specific iTregs was significantly higher than polyclonal iTregs. As controls, OT-II CD41Foxp3- cells
had no effect on GVHD development in OVA- recipients and exacerbated GVHD in OVA1 recipients when
transplanted togetherwith polyclonal Teffs. Because the iTregs recognizeOVAwhereas Teffs recognize alloAg
bm12, our data reveal for the first time, to our knowledge, that Tregs prevent GVHD through a linked sup-
pression. Mechanistically, OT-II iTregs expanded extensively, and significantly suppressed expansion and infil-
tration of Teffs in OVA1 but not in OVA- recipients. These results demonstrate that Ag-specific iTregs can
prevent GVHD efficiently and selectively, providing a proof of principle that Ag-specific iTregs may represent
a promising cell therapy for their specificity and higher efficacy in allogeneic HCT.
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Allogeneic bonemarrow transplantation (BMT) or
hematopoietic cell transplantation (HCT) offers great
promise for the treatment of a variety of diseases in-
cluding cancer, autoimmunity, aplastic anemia, and
other hematopoietic diseases. However, graft-versus-
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6/j.bbmt.2010.12.710following this therapeutic procedure because it leads to
high morbidity and mortality in patients [1,2]. Despite
the magnitude of this complication and the extensive
efforts to overcome this problem, no clinical strategy
has been established to efficiently prevent GVHD
without producing a broad immune suppression.
Recent evidence indicates that the use of Tregs
(CD41Foxp31) is one of the promising approaches to
control GVHD in numerous mouse models [3-8] in
addition to early clinical trials [9].
Although it is widely accepted that natural
CD41Foxp31 Tregs are developed in the thymus
(termed nTregs), accumulating evidence suggests
that T cells with regulatory function may also arise
in the periphery under certain conditions and are
termed induced Tregs (iTregs). The full extent of dif-
ferences and similarities between iTregs and nTregs
has not yet been defined [10]. Due to the infrequency
of nTregs in the peripheral blood and the difficulty
in isolating sufficient nTregs with adequate purity,
much attention has been placed on the use of
in vitro–expanded nTregs with emphasis on retaining309
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on iTregs generated from naive CD41CD25- cells to
obtain a regulatory cell population to suppress immune
responses in vitro and in vivo.However, the use of iTregs
as an immunotherapy is still controversial concerning
their stability in Foxp3 expression [11-15].
Because Tregs need to be activated by their specific
antigen (Ag) to exert their suppressive function, it is
understood that polyclonal populations of Tregs will
only have limited efficacy on a per cell basis to regulate
allogeneic responses due to the low frequency of
alloantigen-reactive Tregs within the whole popula-
tion. Although large numbers of polyclonal Tregs
are capable of preventing GVHD in rodents, broad
polyclonal suppression is expected. Therefore, Ag
specificity of Tregs is critical to selective suppression
mediated by these cells. In experimental autoimmune
disease models, Ag-specific Tregs are highly effective
in controlling autoimmune diabetes, gastritis and en-
cephalomyelitis [16-18]. However, the advantage of
using Ag-specific Tregs in the prevention of GVHD
has not yet been investigated.
We previously generated Ag-specific iTregs by
foxp3 transduction and demonstrated that they persist
long-term in vivo and suppress GVHD in a non-
myeloablative BMTmodel when activated by the cog-
nate Ag, either constitutively expressed or introduced
via immunization [11]. In our previous study, however,
a nonmyeloablative BMT model was used that is not
representative of clinical HCT, and iTregs were gen-
erated through gene transfection. In the current study,
we addressed these two important issues and demon-
strate that TGFb-induced, Ag-specific iTregs effi-
ciently and selectively prevent GVHD in a murine
model of myeloablative BMT.MATERIAL AND METHODS
Mice
C57BL/6 (B6, H-2b), B6 that express congenic
Ly5.1 or Thy1.1, B6 bm12, and OT-II TCR trans-
genic (Tg) strains were purchased from the Jackson
Laboratory (Bar Harbor, ME). Foxp3gfp knock-in
(KI) strain was obtained from Rudensky’s laboratory
at University of Washington (Seattle, WA) [19,20].
Luciferase-transgenic (Luc-Tg) strain on B6 back-
ground was kindly provided by Dr. R. Negrin (Stan-
ford Univ., Stanford, CA) [21]. B6 OVA Tg under b-
actin strain was kindly provided by S. Schoenberger
(La Jolla Institute for Allergy and Immunology, La
Jolla, CA). OT-II Foxp3gfp KI and (B6.OVA 
bm12)F1 strains were produced by cross-breeding.
All the mice were housed in a pathogen-free condition
at H. Lee Moffitt Cancer Center. All experimental
procedures were approved by the Institutional Animal
Care and Use Committee.T Cell Purification and iTreg Generation
CD41CD25- T cells were purified through nega-
tive selection as described in our previous work [22].
The purity of CD41CD25- cells ranged from 85%
to 95%, but CD41CD251 cells were always less than
1% among total CD41 cells. To generate polyclonal
iTregs, CD41CD25- T cells from B6 Foxp3gfp KI
mice were seeded at 2.5  105/ml and stimulated
with 0.5 mg/ml anti-CD3 monoclonal antibody
(mAb) in the presence of 1.25 106/ml irradiated syn-
geneic T cell–depleted (TCD)-splenoctyes as antigen
presenting cells (APCs) with TGF-b1 and IL-2 both
at 2 ng/ml. OT-II Tg iTregs were generated in the
same way, except that 0.5 mM OVA peptide was used
instead of anti-CD3 mAb. After incubation for 4-6
days, cells were harvested for measuring GFP, CD4,
and CD25 expression. Percentage of CD251GFP1
cells ranged from 20% to 60% amongCD41 cells after
4-6 day culture. CD41CD251GFP1 cells were puri-
fied by fluorescence-activated cell sorter (FACS) sort-
ing and used as iTregs, whereas CD41GFP- cells were
used as controls.
Immunofluorescence Analysis
Two-, 3-, or 4 -color flowcytometrywas performed
to measure the expression of surface molecules accord-
ing to standard techniques. Intracellular Foxp3 expres-
sion was measured with a Foxp3 detection kit from
eBioscience (San Diego, CA), according to the manu-
facturer’s instruction. Intracellular cytokinesweremea-
sured after stimulation with PMA1 ionomycin in vitro
for 4-5 h with the addition of GolgiStop for the last 2 h.
The cells were then stained for surface expression of
CD4, Ly5.1, and Thy1.1, and for intracellular expres-
sion of IFN-g and IL-17. Analysis was performed using
a FACS Calibur or LSR II and CellQuest software
(Becton Dickinson, San Jose, CA). Fluorescence-
conjugated Abs were purchased from BD-Pharmingen
(San Diego, CA) or eBioscience (San Diego, CA).
BMTand Bioluminescent Imaging (BLI)
(B6 bm12)F1mice were exposed to 1200 to 1300
cGy (split dose) of total body irradiation. TCD-BM
cells alone or in combination with purified CD41
CD25- T cells from B6 donors were injected via the
tail vein into recipients within 24 h after irradiation.
Recipient mice were monitored every other day for
clinical signs of GVHD, such as ruffled fur, hunched
back, lethargy or diarrhea, and mortality. Animals
judged to be moribund were sacrificed and counted
as GVHD lethality as described in our previous
work [23,24]. In vivo BLI of BALB/c recipients
transplanted with T cells from Luc-Tg B6 donors
and BM from non-Tg B6 donors was performed as de-
scribed previously [23,24], using an IVIS200 charge-
coupled device imaging system (Xenogen).
Biol Blood Marrow Transplant 17:309-318, 2011 311Prevention of GVHD by iTregsStatistical Analysis
The log-rank test was used to detect statistical dif-
ferences in recipient survival in GVHD experiments.
Student’s t test was used to compare percentages or
numbers of donor T cells.RESULTS
TGFb-Induced, Ag-Specific iTregs Prevent
GVHD in an Ag-Dependent Manner
Recent progress made by many groups including
ours indicates that iTregs can be generated from na€ıve
CD4 T cells upon TCR stimulation in the presence of
TGFb [22,25,26]. iTregs are effective in suppressing
autoimmune diseases, but their effect in controlling
GVHD is controversial and remains to be further
investigated. For this reason, we generated OT-II
TCR Tg and foxp3/gfp KI mice by cross-breeding.
OVA-specific iTregs were then generated from OT-II
Tg and foxp3/gfpKICD41CD25-Tcells by stimulating
them with OVA peptide in the presence of TGFb
(Figure 1). We then tested whether OVA-specific
iTregs (CD41CD251GFP1) were able to prevent
GVHD induced by polyclonal T cells in a B6 /
(B6  bm12)F1 BMT model, in which donor CD41
T cells (Teffs) recognize mismatched recipient MHC
II alloAg (H2bm12). To specifically activate iTregs,
(B6.OVA  bm12)F1 mice were used as recipientsFigure 1. Isolation of iTregs and nTregs. Generation and purification of iTre
TCRTg and foxp3/gfp KI mice. These purified T cells were stimulated with OVA
was added in the culture at 2 ng/ml for Treg generation. Four to 6 days after cu
sion. The phenotype of cultured cells is shown on gated live cells (2 left panel
sorting (2 right panels). Purification of nTregs. CD41 cells were isolated throug
These CD41-enriched cells were stained for CD4 and CD25 expression. Th
CD41CD251GFP1 and CD25-GFP- cells were separated by FACS sorting (2that ubiquitously express OVA. The bm12 mutation
can presentOVApeptide, butOT-IIT cells cannot rec-
ognize this MHC/peptide complex. In this setting,
Teffs at the indicated dose induced 50%GVHD lethal-
ity. Similar numbers of OVA1 and OVA- recipients
were used for theTeff alone group, but the same results
were observed in survival or weight loss regardless of
OVA expression (data not shown). Additional iTregs
completely prevented GVHD lethality in OVA1 (p 5
.01) but not in OVA- recipients (p 5 .80) (Figure 2),
indicating that activation of iTregs was required for
their suppressive function. CD41GFP- control cells
had no effect onGVHD inOVA- recipients, or even ac-
celerated GVHD in OVA1 recipients as Teffs
(Figure 2). These results demonstrate that Ag-specific
iTregs are potent in suppressing GVHD in an
activation-dependent manner. Because the iTregs rec-
ognize OVA, whereas Teffs recognize alloAg bm12,
these data reveal that Tregs prevent GVHD through
a linked suppression.TGFb-Induced, Ag-Specific iTregs Are
Significantly More Effective than Polyclonal
iTregs in the Prevention of GVHD
To further evaluate the potency of OVA-specific
iTregs in the prevention of GVHD, these iTregs
were used at 1:4 or 1:8 ratio of Treg:Teff. We found
that GVHD lethality was completely prevented atgs. CD41CD25- cells were purified from spleen and lymph node of OT-II
peptide at 0.5 mM in the presence of irradiated TCD-splenocytes. TGFb
lture, cells were harvested and stained for CD4, CD25, and GFP expres-
s). CD41 CD251GFP1 and CD251GFP- cells were separated by FACS
h negative selection from spleen and lymph node of B6 foxp3/gfp KI mice.
e phenotype of these cells is shown on gated live cells (2 left panels).
right panels).
Figure 2. The effect of TGFb-induced Tregs in GVHD. OVA1 or OVA- (B6  bm12)F1 mice were lethally irradiated and transferred with 5  106
TCD-BM alone or plus 1  106 CD41 T cells (Teffs) from B6 donors. OVA-specific iTregs (CD41CD251GFP1) were generated and purified by FACS
sorting as shown in figure 1. OVA-specific iTregs or controls at 0.5  106/mouse each were added into donor graft. Recipient survival (A) and body
weight changes (B) are shown. Ten recipients were included in each group except that 5 mice were used in GFP1 or GFP2 cells to OVA- groups.
The data are pooled from 2 replicate experiments using a similar setting.
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potency of Ag-specific versus non–Ag-specific iTregs,
polyclonal iTregs were generated from CD41CD25-
cells of B6 foxp3/gfp KI mice by stimulating with anti-
CD3 mAb in the presence of TGFb as shown in our
previous work [22]. In contrast to Ag-specific iTregs,
the polyclonal iTregs had a partial effect only at a 1:2
ratio of Treg:Teff in suppressing GVHD (Figure 3C
and 3D). These data indicate that Ag-specific iTregs
are 8-fold more effective than polyclonal iTregs in
GVHD prevention.Figure 3. The potency of Ag-specific and polyclonal iTregs in suppressing
transferred with TCD-BM alone or plus 1.6  106 CD41CD25- T cells (Teffs
generated from OT-II T cells and were added at 0.2 or 0.4 106 each into dono
transferred with TCD-BM alone or plus 1  106 CD41CD25- T cells (Teffs al
fromWT B6 T cells with anti-CD3 stimulation plus TGFb were added at 0.25 o
weight changes (B and D) are shown. Five or 6 recipients were included in eaAg-Specific iTregs Suppress The Expansion,
Activation and Infiltration of Teffs in Vivo
We next assessed the suppressive effects of Ag-
specific iTregs on Teffs in vivo. Taking advantage of
Luc-Tg mice, the expansion and infiltration of Luc-
Tg Teffs can be measured in vivo over time using
BLI assay. Because a low dose of Teffs (5 105/mouse)
was transferred into B6 mice (black) that are less sensi-
tive for signal detection, no significant BLI signal was
detected on day 7. The BLI detected on days 17 and 28
demonstrate that additional OT-II iTregs significantlyGVHD. A and B, OVA1 (B6 bm12)F1micewere lethally irradiated and
alone) from B6 donors. OVA-specific iTregs (CD41CD251GFP1) were
r graft. C and D, OVA- (B6 bm12)F1 mice were lethally irradiated and
one) from B6 donors. Polyclonal iTregs (CD41CD251GFP1) generated
r 0.5 106 each into donor graft. Recipient survival (A and C) and body
ch group for both experiments.
Figure 4. The effect of Ag-specific iTregs on expansion and infiltration of Teffs. Lethally irradiated OVA1 (B6 bm12)F1 mice were transplanted
with B6 TCD-BM plus 0.5 106/mouse Teffs (CD41CD25-) isolated from Luc-Tg mice on B6 background. One group of recipients was also transferred
with additional 0.25  106/mouse OT-II iTregs (CD41CD251GFP1). Donor Teffs were monitored in recipient mice 17 and 28 days after BMT. (A), an-
imals were imaged from the ventral position for quantification of donor T cells. (B), the average of relative signal intensity of 4 mice per group, and the
data represent one of 2 replicate experiments.
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(Figure 4A and 4B). The distribution of the BLI signal
suggests that the Teffs infiltrated more broadly to liver
and gut without iTregs, whereas Teffs were more con-
strained in spleen with iTregs (Figure 4A).
To further evaluate the effect of iTregs on expan-
sion and activation of Teffs, we transferred Teffs
isolated from B6 Ly5.11 mice and iTregs generated
from Thy1.11 OT-II CD4 precursor (1:2 ratio of
Treg:Teff) along with TCD-BM isolated from normal
B6 donors into OVA1 or OVA- (B6 bm12)F1 recip-
ients. Seven days after BMT, we measured Teffs
(CD41Ly5.11) in recipient spleen and liver
(Figure 5A and 5D). There was an average of 1.9 6
0.4  106/mouse Teffs in the spleen of the recipients
transferred with Teffs alone, 0.9 6 0.1  106 in the
OVA1 recipients transferred with Teffs plus iTregs,
and 1.86 0.8 106 in the OVA- recipients transferredwith Teffs plus iTregs, respectively (Figure 5B). The
data indicate that iTregs significantly reduced Teff ex-
pansion in the OVA1 (p5 .005) but not the OVA- re-
cipients (p5 .80). In the liver, the number of Teffs was
also significantly lower in the OVA1 recipients trans-
ferred with Teffs plus iTregs than those with Teffs
alone (Figure 5E, p5 .004), suggesting that iTregs re-
duced Teff expansion and/or infiltration in recipient
liver, a major GVHD target organ. Because peripheral
lymphoid organs are important for T cell activation,
we examined the migration of iTregs to recipient
lymph nodes and spleen relevant to antigen stimula-
tion in vivo. In a separate experiment, we observed
that the percentages of iTregs among CD41 T cells
were 36.3 6 5.3% vs. 17.1 6 3.1% in lymph nodes
and spleen of OVA1 recipients, respectively (n 5 4,
p5 .0007). However, the percentages of iTregs among
CD41 T cells were similar and less than 1% in lymph
Figure 5. Effects of Ag-specific iTregs on expansion and activation of Teffs. Teffs cells (CD41CD25-) were isolated fromWT Ly5.11 donors and
transferred at 1 106/mouse together with TCD-BM into lethally irradiatedOVA- or OVA1 (B6 bm12)F1 mice. The other 2 groups were transferred
with OT-II Thy1.11 iTregs at 0.5  106/mouse into OVA- or OVA1 (B6  bm12)F1 recipients. Seven days after BMT, recipient spleen (A-C) and liver
(D and E) were harvested for measuring expansion and activation of donor Teffs. A, Top panels show percentages of CD41 cells in live cells, and bottom
panels show expression of Ly5.1 (Teffs’ maker) and Thy1.1 (iTregs’ marker) on gated CD41 live cells in recipient spleen. B, absolute numbers of Teffs
(CD41Ly5.11) are shown in average6 1 SD. C, spleen cells were also measured for intracellular expression of IFNg, and absolute numbers of IFNg1
Teffs (CD41Ly5.11) are shown in average 6 1 SD. D, top panels show percentages of CD41 cells in live cells, and bottom panels show expression of
Ly5.1 (Teffs’ marker) and Thy1.1 (iTregs’ marker) on gated CD41 live cells in recipient liver. E, absolute numbers of Teffs (CD41Ly5.11) in the liver are
shown in average 6 1 SD. Each group includes 3 or 4 mice, and the data represent 1 of 3 replicate experiments.
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These results suggest that Tregs preferentially reside
in lymph nodes upon Ag stimulation.
To evaluate the activation of Teffs, we measured
intracellular expression of IFNg and IL-17, and calcu-
lated the numbers of IFNg- and IL-17-producing
Teffs in the recipient spleen. The number of IFNg-
producing Teffs in the OVA1 recipients transferred
with Teffs plus iTregs was significantly lower thanthat in the recipients of Teffs alone (p 5 0.005),
whereas there was no difference between the recipients
with Teffs alone and those OVA- recipients with
Teffs plus iTregs (p 5 .90) (Figure 5C). There were
very few Teffs that produced IL-17 (\ 2%) and no
significant difference among those groups (data not
shown). These results indicate that iTregs also re-
duced Teff activation when iTregs were activated by
specific Ags.
Figure 6. Expansion and stability of Tregs in the recipients after allogeneic BMT. Experimental setting is the same as described in figure 5. One
additional group of recipients was transferred with 0.5  106/mouse nTregs isolated from na€ıve B6 foxp3/gfp KI mice (Ly5.21Ly5.1-). A, percentages of
Thy1.11Ly5.1- (iTregs) or Ly5.21Ly5.1- cells (nTregs) on gated CD41 live cells in recipient spleen. B, absolute numbers of iTregs or nTregs are shown. C,
absolute numbers of IFNg1 iTregs or nTregs are presented per spleen. D, GFP expression on gated iTregs or nTregs in recipient spleen. E, percentages of
GFP1 cells among gated iTregs or nTregs are shown in average6 1 SD. Each group includes 3 or 4 mice, and the data represent 1 of 3 replicate exper-
iments.
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to Higher Numbers Whereas nTregs Had More
Stable Expression of Foxp3
We assessed the expansion and stability of iTregs
in vivo. In experiments with the same setting as in
figure 5, OT-II iTregs (CD41Thy1.11) expanded
extensively in OVA1 but not OVA- recipients
(Figure 6A and 6B, p\ 0.001). To further compare
the expanding potential between iTregs and nTregs,
we isolated polyclonal nTregs (CD41CD251GFP1)
from na€ıve B6 foxp3/gfp KI mice (Ly5.21) as standard
controls (Figure 1B). The expansion levels for OT-II
iTregs in OVA1 recipients were significantly higher
than that of nTregs (Figure 6A and 6B, p 5 0.001),
indicating that Treg expansion depended on Ag-
stimulation in vivo.
Recent publications suggest that iTregs are less
stable than nTregs in maintaining Foxp3 expression.
To address this concern, we gated on CD41Thy1.11
Tregs and analyzed their Foxp3/GFP expression. Be-
cause Tregs were highly purified through FACS sort-
ing for GFP expression (Figure 1A), the percentage of
GFP- cells in gated CD41Thy1.11 cells would reflect
the loss of Foxp3 expression. Polyclonal nTregs
(CD41CD251GFP1) from na€ıve B6 foxp3/gfp KI
mice were also used as standard controls. Under mye-
loablative allogeneic BMT, an average of 43.6 6
5.4% nTregs kept their GFP expression 7 days after
cell transfer, whereas 29.4 6 2.8% and 24.8 6 2.8%
iTregs kept their GFP in OVA1 and OVA- recipients,
respectively (Figure 6D and 6E). Foxp3 expression was
less stable in iTregs than nTregs (p 5 0.003), whereas
the stability of iTregs was similar in the recipients re-
gardless of OVA expression (Figure 6D and E). Tomeasure activation of Tregs, intracellular IFNg and
IL-10 were measured. We found that 7 days after
BMT there was an average of 20.0 6 3.4% and 4.1 6
0.5% IFNg1 cells among Ag-specific iTregs and
polyclonal nTregs, respectively. Furthermore, the
number of IFNg1 Ag-specific iTregs was significantly
more in the OVA1 than OVA- recipients and signifi-
cantly more than that of nTregs in recipient spleen
(Figure 6C, p\0.001). In conclusion, Treg expansion
depended on Ag-stimulation, and iTregs were acti-
vated and expanded more extensively than nTregs,
but iTregs were less stable than nTregs in Foxp3 ex-
pression upon Ag-stimulation under myeloablative
allogeneic BMT.DISCUSSION
Besides regulating autoimmunity, CD41CD251
Tregs also control allogeneic responses. Therefore, re-
search on understanding and applyingTregs in the set-
ting of HCT has been an active field in recent years
[27]. Due to the low frequency of nTregs, current
approaches attempting to apply Tregs in clinical
HCT are focused on adoptive transfer of polyclonal,
ex vivo–expanded, nTregs into transplant recipients
before or after stem cell transplantation. Isolating
and expanding polyclonal nTregs is feasible [28,29];
however, questions remain about their efficacy and
the consequences of broad immune suppression
in vivo. For example, these polyclonal nTregs may
have a low potency in controlling GVHD and
produce non-selective immune suppression without
discriminating for GVH and GVL reactions.
316 Biol Blood Marrow Transplant 17:309-318, 2011K. Semple et al.The current study is aimed at increasing the
potency and selectivity of Treg therapy. By using
TGFb-induced Ag-specifc iTregs, we showed that
Ag-specific iTregs were highly effective in preventing
GVHD in a clinically relevant murine model of alloge-
neic BMT in an Ag-dependent manner (Figure 2). The
current study substantially extended the previous work
by us and others showing that in vitro–generated iTregs
were effective in suppressing allogeneic responses in
bone marrow or solid organ transplantation [11-14].
However, our result is in contrast to a recent report
by Koenecke et al. that TGFb-induced polyclonal
iTregs were not effective in preventing GVHD,
presumably due to the instability of Foxp3 expression
[15]. We interpret that the differences in the protocol
of generating iTregs, the specificity of iTregs and
GVHDmodel may contribute to the distinct outcome
in these two studies. Higher levels in expression of Ag-
specific iTregs likely resulted from higher levels of Ag-
driven proliferation and were less dependent on Ag and
cytokine signals in recipients of preactivated and divid-
ing iTregs versus resting nTregs.
A potential concern is that iTregs may not have
stable Foxp3 expression due to their status of epige-
netic modification and lose their suppressive activity
in vivo [30]. In fact, some studies have shown that
in vitro–generated iTregs were less suppressive than
nTregs [31,32]. However, there is also substantial
evidence in the literature supporting that iTregs
were as or more effective than nTregs in suppressing
immune responses in vivo [16,18,25,33-37]. To
address this concern on iTreg stability, we directly
compared Foxp3 stability of iTregs and nTregs and
observed that iTregs were less stable than nTregs in
Foxp3 expression under allogeneic BMT (Figure 6D
and E). However, iTregs underwent substantially
higher levels of Ag-driven expansion than nTregs
(Figure 6B), which may compensate for their inferior
stability relative to that of nTregs. Remarkably, we
showed that Ag-specific iTregs were able to prevent
GVHD in 100% recipients at a 1:8 ratio of Tregs to
Teffs (Figure 3A). In contrast, using the same murine
BMT model in which BM plus CD41 T cells were
transplanted into lethally irradiated bm12 recipients,
Taylor et al. indicated that in vitro–activated and ex-
panded, polyclonal CD62Lhigh nTregs could prevent
GVHD in nearly 100% at a 3:1 ratio of Tregs to Teffs
[7]. Taken together, these data suggest that Ag-specific
iTregs can be 24-fold more effective than the most
potent polyclonal nTregs tested so far. Considering
the frequency of alloreactive T cells, we observed
that significantly more Ag-specific iTregs produced
IFNg after activation by cognate Ag than polyclonal
nTregs after activation by alloantigens (20% vs. 4%),
confirming that Ag-specific iTregs were more acti-
vated than polyclonal nTregs. Because IFNg produc-
tion by Tregs is critical for their suppressive functionin vivo [38], the high level of IFNg production by
Ag-specific iTregs also correlated with their superior
suppressive activity to polyclonal nTregs.
A fundamental issue regarding Treg-mediated
suppression not yet being addressed is whether
Tregs execute their regulatory function through Ag-
specific, Ag-linked, or bystander suppression in vivo.
The current studymade it clear that iTregsmust be ac-
tivated by their cognate Ag in vivo in order for them to
exert their suppressive function and to control GVHD
(Figures 2 and 3). Because iTregs recognize nominal
Ag (OVA), whereas Teffs recognize allo-Ags (bm12),
the results indicate that iTregs do not have to recog-
nize the same Ag as Teffs for Tregs to suppress the re-
sponses elicited by the Teffs in vivo and strongly
support the notion that linked suppression is opera-
tional under allogeneic BMT settings. Our data are
consistent with the results reported by Tang et al.
that monoclonal Tregs (BDC2.5 TCR Tg) specific
for an islet Ag are highly effective in controlling exper-
imental diabetes induced by polyclonal diabetogenic
Teffs [17]. These studies indicate that Treg-
mediated immunosuppression does not have to be ex-
clusively Ag-specific, which seems contradictory to the
results observed by Joffre et al. [39] or those by Zhang
et al. [18]. Using a BM rejection model, Joffre et al.
showed that Tregs specific for donor alloAgs selec-
tively prevent rejection of donor BM but not third-
party BM, both of which were transplanted into the
same recipient [39], suggesting that Treg-mediated
suppression is Ag-specific. Likewise, using an EAE
model, Zhang et al. showed that myelin proteolipid
protein (PLP)139-151–specific iTregs were effective at
suppressing EAE induced by the cognate (PLP)139-151
peptide, but not by (PLP)178-191 peptide or even a mix-
ture of the 2 peptides [18]. It is not clear why Tregs
mediated suppression with exquisite Ag-specificity
in some studies but not others. What is clear is that
Tregs can induce Ag-specific or Ag-linked suppression
but not bystander suppression in vivo. No bystander
suppression in vivo is also evident in which the gener-
ation of donor-reactive iTregs prevents graft rejec-
tion without compromising immunity to a viral
pathogen [40].
Isolating and expanding polyclonal nTregs has
been shown to be feasible [28,29]; however, questions
remain about their efficacy and Ag specificity in vivo.
For example, although they can be expanded
multifold in vitro, generating the absolute number of
Tregs needed to treat a patient successfully may still
be a challenge [27]. We want to emphasize that, unlike
polyclonal alloreactiveTregs expandedwith allogeneic
APCs in vitro [41-43] or induced in vivo [44-46], theAg-
specific Tregs investigated in the current study are
monoclonal and each of them specifically recognizes
the cognate Ag, which likely contributes to the high
efficacy of these cells in suppressing GVHD. In this
Biol Blood Marrow Transplant 17:309-318, 2011 317Prevention of GVHD by iTregsproof-of-concept study, the iTregs aremonoclonal and
uniformly recognize the cognized antigen with high af-
finity, thus caution should be noted from a translational
perspective, as the results could be different with a pop-
ulation of polyclonal Ag-specific iTregs. Our current
effort focuses on evaluating the effects of polyclonal
iTregs specific forMHCormiHAAgs for better trans-
lational potential. The current study also provides evi-
dence that iTregs prevent GVHD through linked
suppression in an Ag-activation dependent manner,
which likely has a broad impact in understanding how
Tregs execute their suppressive function under
biological or pathological situations. In clinical appli-
cation, this finding indicates that iTregs specific for
a miHA restricted on parenchymal tissues can distin-
guish GVHD versus GVL. Although creating Ag-
specific Tregs is facilitated by the use of TCR Tg cells
in mice, this approach will be more challenging in hu-
mans. However, the approach can be applied in the
clinic to treat hematological tumors by generating
and using iTregs specific for restricted miHAs on
GVHD target tissues, because human T cells can be
primed by miHAs in vitro. In conclusion, this study
provides a proof of principle that Ag-specific iTregs
may represent a promisingTreg therapy for their spec-
ificity and higher efficacy in allogeneic HCT.ACKNOWLEDGMENTS
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